Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Alexion Pharmaceuticals"
Count: 194
Selected: 0
NCT IDTitle
NCT05047484A Study of Multiple Doses of ALXN2050 in Healthy Adults
NCT05047458A Study of Single-dose ALXN2050 in Healthy Adults
NCT05016206A Study of the Cardiac Effects of Danicopan in Healthy Adults
NCT03555539Study of Danicopan in Participants With Hepatic Impairment
NCT03384186A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants
NCT03124368A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
NCT04940559Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants
NCT03472885Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab
NCT03108274A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants
NCT04935294Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction
NCT03053102Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04889690Study of Multiple Doses of Danicopan in Healthy Participants
NCT04889677Study of a Single Dose of Danicopan in Healthy Participants
NCT04889391Study of Radiolabeled Danicopan in Healthy Male Participants
NCT03181633A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT00040144Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B
NCT00034359Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection
NCT05047523Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
NCT05019521A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT03403205Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease With an Extension Period of up to 60 Months
NCT04999020Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
NCT04982289Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis
NCT04980248Study of ALXN1850 in Participants With Hypophosphatasia (HPP)
NCT04610580Bioavailability Study of 2 Oral Formulations of ALXN1840
NCT04573309Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
NCT04557735Study of Ravulizumab in Pediatric Participants With HSCT-TMA
NCT04543591Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant
NCT04526210Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
NCT04526197Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.
NCT04970004Retrospective Observational Study in Adult and Pediatric Patients With HSCT-TMA
NCT04709094A Drug Interaction Study of Danicopan
NCT04709081A Drug Interaction Study of ACH-0145228
NCT04155424A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
NCT04958135Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants
NCT04956276Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia
NCT03759366A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
NCT03661528Trial of Andexanet in ICH Patients Receiving an Oral FXa Inhibitor
NCT04952545Study of ALXN2050 in Healthy Adult Participants of Japanese Descent
NCT04233073Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery
NCT04933682Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants
NCT04564339Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
NCT04730804A Study of ALXN1830 in Healthy Adult Participants
NCT04422431Copper Concentration and Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840
NCT04920370Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects
NCT04320602Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab
NCT04469465Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)
NCT04622046A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM
NCT04170023Proof of Concept Study of ACH-0145228 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT03369236A Proof of Concept Study for 6 Month Treatment in Patients With C3 Glomerulopathy (C3G)
NCT04369469Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia